Abstract【Objective】 To analyze the safety and efficacy of vortioxetine in first-episode major depressive disorder patients. 【Method】 One hundred and twenty-three patients with major depression were randomly divided into two groups: the observation group (10 mg / D of vothixetine, n=61) and the control group (60 mg / D of duloxetine, n=62). The scores of HAMD-17 and SDS, HAMA and SAS were used as the main therapeutic indexes. Adverse reactions were recorded by side effect scale in safety assessment.【Results】 The effective rate of the observation group was 75.4%, the effective rate was 91.8%; the effective rate of the control group was 66.1%, the effective rate was 88.7%. There was no significant difference between the two groups in demonstrating efficiency and efficiency(P>0.05). After treatment, the HAMD scores of the two groups were lower than before treatment, the difference was statistically significant (P<0.05); the HAMD scores of the observation group were lower than that of the control group after 2 weeks of treatment, the difference was statistically significant (P<0.05). After 8 weeks of treatment, the scores of HAMA, HAMD, SDS and SAS in the two groups were significantly lower than those before treatment (P<0.05). There were 16 cases (26.2%) in the observation group and 18 cases (29.0%) in the control group. There was no significant difference between the two groups (P>0.05).【Conclusion】 The efficacy of vortioxetine in the treatment of depression is similar to that of duloxetine. Vortioxetine can relieve the depressive symptoms quickly and effectively, and can improve the anxiety symptoms of patients with depression, with good safety and tolerance.
YANG Dong,YU Yan,LIU Li-ni. Clinical Effect of Vothixetine in the Treatment of First Major Depression[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(5): 674-676.
[1] Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder[J].Expert Opin Drug Discov,2019, 14(1):81-89. [2] Long JD. Vortioxetine for depression in adults[J].Issues Ment Health Nurs,2019, 40(9):819-820. [3] 王创. 氢溴酸伏硫西汀治疗重度抑郁障碍的临床疗效及安全性评价[J].北京医学,2019,41(5):425-426. [4] 喻妍,杨栋,彭红莉,等. 米氮平与舍曲林治疗首发抑郁症对认知功能影响的对照研究[J].医学临床研究, 2016, 33(12): 2292-2295. [5] Sowa-Ku'ma M, Pańczyszyn-Trzewik P, Misztak P,et al. Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant[J].Pharmacol Rep,2017, 69(4):595-601. [6] 杨洁,王刚. 新型5-羟色胺再摄取抑制剂的抗抑郁治疗:多受体效应与临床作用[J].中华精神科杂志,2018, 51(2): 145-148. [7] Anne Yee, Chong Guan Ng, Loh Huai Seng.Vortioxetine treatment for anxiety disorder: a meta-analysis study[J].Curr Drug Targets,2018,19(12):1412-1423. [8] Frampton JE.Vortioxetine: a review in cognitive dysfunction in depression[J].Drugs,2016,76(17):1675-1682. [9] Areberg J, Luntang-Jensen M, S gaard B, et al. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects[J].Basic Clin Pharmacol Toxicol,2012, 110 (4):401-404.
2020, Vol. 37 
